From Diagnosis to Cure: An Integrated Health System Baby Boomer HCV Screening and Therapy Management Program
AASLD LiverLearning®, James Levin, 195084
Treatment of chronic HCV following renal transplantation: A US Experience
AASLD LiverLearning®, Richard Sterling, 195106
Impact of Direct Acting Antiviral (DAA) for HCV Treatment on Liver Transplant Outcomes: A Multicenter 15-year Experience.
AASLD LiverLearning®, Omar Mousa, 195223
The Fat Conundrum: When Diet Alone is Not Enough
AASLD LiverLearning®, Michael Fuchs, 202067
Concluding Remarks
AASLD LiverLearning®, Clifford Steer, 202055
Nutrition for Patients With Cirrhosis: Is Protein Restriction Necessary?
AASLD LiverLearning®, Amanda Chaney, 202066
Bottoms Up: Approaching the Cholestatic Liver from the Gut
AASLD LiverLearning®, James Tabibian, 202041
Genome Editing and Hepatocyte Transplantation
AASLD LiverLearning®, Raymond Hickey, 202054
Health Disparities
AASLD LiverLearning®, Benjamin Cook, 202075
Supportive Care Versus Hospice Care for End-stage Liver Disease
AASLD LiverLearning®, Cristal Brown, 202065
Fibrates: Have We Had the Best Treatment for Cholestatic Liver Diseases on the Shelf for Years?
AASLD LiverLearning®, Cynthia Levy, 202040
Gene Editing and the Next Generation of Antiviral Therapy
AASLD LiverLearning®, Keith Jerome, 202053
Mixed Methods Approaches
AASLD LiverLearning®, Jessica Mellinger, 202074
Session II Moderator
AASLD LiverLearning®, Maria Yataco, 202062
Session II Moderator
AASLD LiverLearning®, Cheryl Dale, 202063
Pregnancy and Liver Disease
AASLD LiverLearning®, Tram Tran, 202064
Behavioral and Health Economics
AASLD LiverLearning®, David Goldberg, 202073
Dual AAV Cas9-Mediated Correction of Metabolic Liver Diseases
AASLD LiverLearning®, Lili Wang, 202052
Quality Improvement
AASLD LiverLearning®, Elliott Tapper, 202072
Targeted Immunosuppression for Autoimmune Cholestatic Liver Diseases
AASLD LiverLearning®, Gideon Hirschfield, 202038
Program Chair
AASLD LiverLearning®, Michael Volk, 202070
Methods for Conducting Healthcare Delivery Research
AASLD LiverLearning®, Lisa VanWagner, 202071
Session II Moderator
AASLD LiverLearning®, R. Scott Mclvor, 202049
Session II Moderator
AASLD LiverLearning®, Mark Kay, 202050
Proof-of-Concept for Non Nuclease Mediated Genome Editing to Treat Alpha1- Antitrypsin Deficiency
AASLD LiverLearning®, Christian Mueller, 202051
Clinical Practice SIG: Best Practices in Clinical Hepatology: Wrap Up
AASLD LiverLearning®, Marcelo Kugelmas, 202031
Manipulating the Bile Acid Pathway to Treat Cholestatic Liver Diseases
AASLD LiverLearning®, Marlyn Mayo, 202037
Management of Complications of Loco-regional Liver Tumor Therapy
AASLD LiverLearning®, Rhonda Martin, 202061
Bile Acids as Therapeutic Drugs
AASLD LiverLearning®, Marina Silveira, 202036
Thomas E. Starzl Transplant SOA: Equity in Access to Organ Allocation
AASLD LiverLearning®, John Lake, 202068
Thomas E. Starzl Transplant SOA: Equity in Access to Organ Allocation
AASLD LiverLearning®, Julie Heimbach, 202069
Genome Editing in the Liver without the Use of Nucleases
AASLD LiverLearning®, Mark Kay, 202048
The Enterohepatic Circulation
AASLD LiverLearning®, Saul Karpen, 202035
Portal Vein Thrombosis: Work up and Management
AASLD LiverLearning®, Nicolas Intagliata, 202060
Controversies in Management of Portal Hypertension
AASLD LiverLearning®, Marcelo Kugelmas, 202029
Introduction, Goals and Structure of the Workshop
AASLD LiverLearning®, Mario Strazzabosco, 202032
Introduction, Goals and Structure of the Workshop
AASLD LiverLearning®, Marlyn Mayo, 202033
Therapeutic Gene Editing via Viral and Non-viral Delivery Systems
AASLD LiverLearning®, Daniel Anderson, 202047
Pulmonary Complications of Cirrhosis: Portopulmonary Hypertension and Hepatopulmonary Syndrome/Transplant Issues
AASLD LiverLearning®, David Goldberg, 202059
Modeling Liver Diseases in Vivo with CRISPR/Cas9
AASLD LiverLearning®, Wen Xue, 202046
Multidisciplinary Approach to the Management of Hepatocellular Carcinoma
AASLD LiverLearning®, Mitchell Shiffman, 202028
Zinc Finger Mediated, Site-Specific Genome Engineering in the Treatment of Mucopolysaccharidosis
AASLD LiverLearning®, R. Scott Mclvor, 202045
Session I Moderator
AASLD LiverLearning®, Cynthia Solomon, 202056
Session I Moderator
AASLD LiverLearning®, Patrick Horne, 202057
HCV Therapy Update: Resistance and New Treatments
AASLD LiverLearning®, Daniel Tassone, 202058
Management of NASH
AASLD LiverLearning®, Kris Kowdley, 202027
Sustained Virological Response 12 Weeks after Therapy (SVR12) with Direct-Acting Antivirals (DAA) in Select Asian Populations with Chronic Hepatitis C Genotype 1 (HCV GT 1): A Meta-Analysis of Real-World Effectiveness from Asia
AASLD LiverLearning®, Mindie Nguyen, 195069
Immature myeloid cells have an important role of gut bacteria-associated infection in alcoholics
AASLD LiverLearning®, Yusuke Tsuchimoto, 194826
Real World Hepatitis B Virus Screening Rates in Hepatitis C patients treated with Direct-Acting Antiviral Agents
AASLD LiverLearning®, Susanne Shokoohi, 195082
Systems-Wide Characterization of Alcoholic Hepatitis using proteomics of PBMCs
AASLD LiverLearning®, Jon Jacobs, 194827
Safety and Efficacy of 8-weeks Ledipasvir/Sofosbuvir Combination in Chronic Hepatitis C Genotype 4-Infected Patients
AASLD LiverLearning®, Mohamed Babatin, 195083
Alcohol exposure promotes epigenetic changes leading to loss of HNF4α
AASLD LiverLearning®, Irina Tikhanovich, 194842
Receiving directly acting antivirals (DAAs) for hepatitis C improves renal function in patients with CKD regardless of SVR
AASLD LiverLearning®, Mustafa Khan, 195098
Acute-On-Chronic Alcohol Induces Adipose Tissue Atrophy, Hepatic Steatosis and Liver Injury via Inhibition of mTOC1 in Adipose Tissue in Mice
AASLD LiverLearning®, Yuan Li, 194843
Direct Acting Antivirals in Hepatitis C Virus Genotype 3 and Advanced Cirrhosis
AASLD LiverLearning®, Virendra Singh, 195099
Good relationship between RIPK3-mediated necroptosis with neutrophil-mediated alcoholic liver inflammation and the prognosis
AASLD LiverLearning®, Zhenzhen Zhang, 194858
Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1a) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)
AASLD LiverLearning®, Bruce Bacon, 195114
Transcriptomics of liver tissue, PBMCs, and monocytes in alcoholic hepatitis
AASLD LiverLearning®, Trina Norden-Krichmar, 194859
On-treatment HCV RNA kinetics do not predict SVR in patients treated for 12 weeks with sofosbuvir plus an NS5A inhibitor
AASLD LiverLearning®, Slim Fourati, 195115
Elbasvir, Grazoprevir; with or without Ribavirin and its Effectiveness with Sofosbuvir resulting SVR in chronic hepatitis C genotype 1 prior experienced co-infected individuals. A randomized open label clinical prospective trial: EGRESS - C
AASLD LiverLearning®, Menisa Zaman, 195130
A Novel and Direct Interaction Between Large and Small GTPases Mediates Autophagic Lipid Droplet Breakdown in Hepatocytes
AASLD LiverLearning®, Zhipeng Li, 194875
Comparing Direct Acting Antivirals-Based Regimens Plus Ribavirin in Treatment-Experienced Hepatitis C Virus Genotype 3 Patients: A Systematic Review and Meta-Analysis
AASLD LiverLearning®, Muhammad Ali Khan, 195131
State of activation of Hepatic Stellate Cells determines their role in Hepatocellular Carcinoma progression or arrest
AASLD LiverLearning®, Dola Das, 194890
Real-world effectiveness and cost per svr of sofosbuvir/velpatasvir chronic hepatitis c treatment
AASLD LiverLearning®, Peter Buggisch, 195146
The divergent roles of matriptase and HAI-1 in human hepatocyte and biliary duct epithelium
AASLD LiverLearning®, Yee Hui Yeo, 194891
Cost-effectiveness of sofosbuvir/ribavirin in patients with genotype 2 chronic hepatitis C: An analysis with real-world outcomes from a multicenter cohort in Japan
AASLD LiverLearning®, Norihiro Furusyo, 195147
Cancer surveillance in primary sclerosing cholangitis is associated with improved clinical outcomes.
AASLD LiverLearning®, Ahmad Ali, 194906
Sorafenib versus transarterial chemoembolization plus external beam radiotherapy in patients with hepatocellular carcinoma with major vascular invasion (START): a randomized phase 2 trial
AASLD LiverLearning®, Sang Min Yoon, 194907
Utility of a new function in 3D Sim-Navigator: electric field, which indicates the predicted ablative area
AASLD LiverLearning®, Azusa Sakamoto, 195163
The Association Between Tumour Size and Overall Survival in Surgically Resected Patients with Intrahepatic Cholangiocarcinoma: A Population-based Study.
AASLD LiverLearning®, Suriya Aktar, 194922
Sofosbuvir-based therapy is associated with higher incidence of de-registration for clinical improvement in hepatitis C patients awaiting liver transplantation: Analysis of SRTR-Symphony Database
AASLD LiverLearning®, W. Ray Kim, 195178
Sarcopenia measured by psoas muscle index is an independent factor for mortality in Korean patients with hepatocellular carcinoma who underwent curative hepatic resection
AASLD LiverLearning®, Hee Yoon Jang, 194923
Is the incidence of liver cancer increased after DAA treatment of chronic hepatitis C?
AASLD LiverLearning®, Gloria Sanchez Antolin, 194938
Variability in acceptance of organ offers by pediatric liver transplant centers and its impact on waitlist mortality
AASLD LiverLearning®, Ellen Mitchell, 195194
Using Nomogram of the Barcelona Clinic Liver Cancer System for Treatment Selection in Patients with Stage C Hepatocellular Carcinoma
AASLD LiverLearning®, Chia-Yang Hsu, 194939
Osteopontin predicts the prognosis of patients with single nodule or early-stage hepatocellular carcinoma and should be associated with the microenvironment of background liver
AASLD LiverLearning®, Kaoru Tsuchiya, 194954
The New Event of Portal Vein Thrombosis Following Adult-to-Adult Living Donor Liver Transplantation does not Affect Long-Term Outcomes
AASLD LiverLearning®, Ivan Linares Cervantes, 195210
Treatment Patterns and Healthcare Costs by Lines of Therapy in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
AASLD LiverLearning®, Machaon Bonafede, 194955
Liver Resection for BCLC 0-A Stage Hepatocellular Carcinoma Does Time to Surgery Impact Outcomes?
AASLD LiverLearning®, Daniel Azoulay, 194970
Increased rejection-risk measured with allospecific T-cells is associated with delayed immunosuppression minimization in children with liver transplantation.
AASLD LiverLearning®, Rakesh Sindhi, 195226
Immunohistochemical detection of markers for hepatic adenoma in steatohepatitic hepatocellular carcinoma
AASLD LiverLearning®, Makiko Taniai, 194971
FIB-4 Index, the Easy Liver Fibrosis Test, and Prediction of Hepatocellular Carcinoma Development in Patients with Compensated Alcoholic Liver Cirrhosis
AASLD LiverLearning®, Minjong Lee, 194986
Non-alcoholic steatohepatitis is an important growing indication for liver transplantation in Australia and New Zealand.
AASLD LiverLearning®, Luis Bertot, 195242
Clinical impact of globulin albumin score on outcome after surgery for patients with hepatocellular carcinoma.
AASLD LiverLearning®, Takayuki Shimizu, 194987
Long-term Outcome After Radiofrequency Ablation for Hepatocellular Carcinoma With Special Interest to Anti-viral Therapy
AASLD LiverLearning®, Ryosuke Tateishi, 195002
Metabolic syndrome and the risk of cardiovascular disease after pediatric liver transplantation in long-term recipients.
AASLD LiverLearning®, Piotr Czubkowski, 195258
Baseline ALBI grade and its time course are predictive factors of prognosis and Child-Pugh grade worsening in patients who underwent initial TACE
AASLD LiverLearning®, Yutaka Yasui, 195003
Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model
AASLD LiverLearning®, Nelson Hayes, 195018
Everolimus Post Liver Transplantation: A Systematic Review
AASLD LiverLearning®, Khalid Bzeizi, 195274
Analysis of polyploidy of human hepatocytes isolated from hepatitis B virus-infected chimeric mice with humanized liver
AASLD LiverLearning®, Yuji Ishida, 195019
Single-Nucleotide-Level Analysis of Evolution and Compartmentalization of Complete Hepadnavirus Genome during Virus Passage in Hosts Developing Chronic Hepatitis and Hpatocellular Carcinoma
AASLD LiverLearning®, Thomas Michalak, 195034
Intracellular HBV degradation is associated with Notch signaling inhibition via ITCH in a ubiquitin proteasome-dependent manner
AASLD LiverLearning®, ZIJING WANG, 195035
Serum Caspase-1 Level as a Diagnostic and Prognostic Biomarker for HBV-Related Acute-on-chronic Liver Failure
AASLD LiverLearning®, Feng Ren, 194794
A liver-derived secretory protein, LECT2, activates plasmacytoid dendritic cells and protects hepatocytes from HBV infection
AASLD LiverLearning®, Takayoshi Shirasaki, 195050
ADAMTS13 deficiency exacerbates acute liver failure with enhanced VWF accumulation and hepatic inflammation in mice.
AASLD LiverLearning®, Hiroaki Takaya, 194795
Identification of novel HLA- A*2402-restricted endogenous CTL epitopes derived from HBV genotype C
AASLD LiverLearning®, Daisuke Yamamiya, 195051
Hepatic Cell Microencapsulation for External Bioartificial Liver : Performance of Spheroids versus Isolated Cells
AASLD LiverLearning®, Jean-Charles Duclos-Vallee, 194810
Real-World Effectiveness of Sofosbuvir-based Regimens for Treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BC-HTC)
AASLD LiverLearning®, Maryam Darvishian, 195066
Validation of TPPM Score in predicting short-term survival in HBV-ACLF patients: a multinational study from APASL ACLF Research Consortium (AARC)
AASLD LiverLearning®, Tao Chen, 194811
Real-world Effectiveness (RWE) of Sofosbuvir+Ribavirin (SOF+RBV) Chronic Hepatitis C Genotype 2 (CHC GT 2) in Asia: A Systemic Review and Meta-analysis of Pooled SVR12
AASLD LiverLearning®, Bin Wei, 195067